These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24969823)

  • 41. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan.
    Moriguchi H
    Dev Biol Stand; 1996; 88():143-7. PubMed ID: 9119127
    [No Abstract]   [Full Text] [Related]  

  • 42. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
    Immelmann A
    Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overview of the animal health drug development and registration process: an industry perspective.
    Hunter RP; Shryock TR; Cox BR; Butler RM; Hammelman JE
    Future Med Chem; 2011 May; 3(7):881-6. PubMed ID: 21644833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Herbal products in Canada. How safe are they?
    Kozyrskyj A
    Can Fam Physician; 1997 Apr; 43():697-702. PubMed ID: 9111986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An audit of health products advertised for sale on chiropractic Web sites in Canada and consideration of these practices in the context of Canadian chiropractic codes of ethics and conduct.
    Page SA; Grod JP
    J Manipulative Physiol Ther; 2009; 32(6):485-92. PubMed ID: 19712792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MotherNature: establishing a Canadian research network for natural health products (NHPs) during pregnancy and lactation.
    Koren G; Dugoua JJ; Magee L; Vohra S; Matsui D; Bérard A; Johnson B; Moretti M; Einarson A
    J Altern Complement Med; 2008 May; 14(4):369-72. PubMed ID: 18466066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Over-the-counter medications and self-care.
    Lowe NK; Ryan-Wenger NM
    Nurse Pract; 1999 Dec; 24(12):34-44. PubMed ID: 10635517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.
    Gibson SG; Lemmens T
    Med Law Rev; 2014; 22(2):200-20. PubMed ID: 24841527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Legal issues concerning the promotion of pharmaceutical products on the internet to consumers.
    Reichertz PS
    Food Drug Law J; 1996; 51(3):355-65. PubMed ID: 11797712
    [No Abstract]   [Full Text] [Related]  

  • 50. Canadian drug regulatory framework.
    Kelly L; Lazzaro M; Petersen C
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S3-10. PubMed ID: 17469674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(27):5942-3. PubMed ID: 11837282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantification of three chiral flavonoids with reported bioactivity in selected licensed Canadian natural health products and US marketed dietary supplements.
    Sayre CL; Davies NM
    J Pharm Pharm Sci; 2013; 16(2):272-8. PubMed ID: 23958196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experimental product testing of biomedicines].
    Vieths S; Seitz R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1131-2. PubMed ID: 25200486
    [No Abstract]   [Full Text] [Related]  

  • 54. Natural health product use in Canada: analysis of the National Population Health Survey.
    Singh SR; Levine MA
    Can J Clin Pharmacol; 2006; 13(2):e240-50. PubMed ID: 16921199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An innovative model for regulating supplement products: natural health products in Canada.
    Nestmann ER; Harwood M; Martyres S
    Toxicology; 2006 Apr; 221(1):50-8. PubMed ID: 16472903
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
    Wisher M
    Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.